Back to User profile » Dr Jian Li
Papers published by Dr Jian Li:
High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients
Dai Y, Pan B, Zhao J, Cai S, Li J, Zou B
Journal of Hepatocellular Carcinoma 2026, 13:600072
Published Date: 14 April 2026
Higher Expression of Ku80 and Ku70 Indicates Hotter Tumor Immune Microenvironment in Hepatocellular Carcinoma and Better CTL-Centered Immunotherapy
Yang L, Li L, Li P, Chen J, Cai C, Jia Y, Li J, Zou B
Journal of Inflammation Research 2024, 17:9511-9525
Published Date: 22 November 2024
Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway
Tong J, Cong L, Jia Y, He BL, Guo Y, He J, Li D, Zou B, Li J
Diabetes, Metabolic Syndrome and Obesity 2022, 15:3285-3301
Published Date: 27 October 2022
Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α
Zhao J, Lin E, Cai C, Zhang M, Li D, Cai S, Zeng G, Yin Z, Wang B, Li P, Hong X, Chen J, Zou B, Li J
Drug Design, Development and Therapy 2022, 16:3197-3213
Published Date: 19 September 2022
Nuclear GAPDH is vital for hypoxia-induced hepatic stellate cell apoptosis and is indicative of aggressive hepatocellular carcinoma behavior
Gong Y, Zou B, Peng S, Li P, Zhu G, Chen J, Chen J, Liu X, Zhou W, Ding L, Chen Y, Zeng L, Zhang B, Cai C, Li J
Cancer Management and Research 2019, 11:4947-4956
Published Date: 30 May 2019
A novel 12-marker panel of cancer-associated fibroblasts involved in progression of hepatocellular carcinoma
Zou B, Liu X, Gong Y, Cai C, Li P, Xing S, Pokhrel B, Zhang B, Li J
Cancer Management and Research 2018, 10:5303-5311
Published Date: 5 November 2018